Hongchang International Co., Ltd (HCIL) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · OTC
Hongchang International Co., Ltd (HCIL) stock forecast summary
On Oct. 16, 2026, HCIL is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5184 stocks scored that day.
Its market capitalization is not available, so no size classification is given.
For HCIL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 3.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 13.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, HCIL included.
Follow HCIL freeHCIL price chart and AI forecast
How HCIL ranks among 5184 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Hongchang International Co., Ltd (HCIL) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Electromedical & Electrotherapeutic Apparatus peers listed below that report each metric.
Valuation & Market
| Metric | HCIL | Rank |
|---|---|---|
| EPS | $0.00 | – |
Profitability & Margins
| Metric | HCIL | Rank |
|---|---|---|
| ROE | 1.3% | 10/19 |
| ROA | 0.8% | 10/24 |
| ROIC | -0.0% | 12/23 |
| Gross Margin | 10.1% | 26/27 |
| Operating Margin | -0.2% | 10/28 |
| Net Margin | 7.0% | 7/22 |
| EBT Margin | -1.8% | 11/28 |
| Tax Rate | -1.1% | – |
Financial Health
| Metric | HCIL | Rank |
|---|---|---|
| Current Ratio | 0.85x | 27/30 |
| Quick Ratio | 0.84x | 24/29 |
| D/E Ratio | 0.52x | 16/25 |
| Financial Leverage | 1.56x | 16/25 |
| Interest Coverage | -1.0x | 11/30 |
| Working Capital | -$2M | 27/29 |
Cash Flow
| Metric | HCIL | Rank |
|---|---|---|
| Operating Cash Flow | -$5M | 19/30 |
Operational Efficiency
| Metric | HCIL | Rank |
|---|---|---|
| Inventory Turnover | 82.8x | 1/27 |
| Days Inventory | 4 days | 27/27 |
Income Statement
| Metric | HCIL | Rank |
|---|---|---|
| Operating Income | -$20K | 11/30 |
| Net Income | $550K | 10/24 |
| Cost of Goods Sold | $4M | 21/27 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $8M | 12.4% of assets |
| Cash & Short-term Investments | $550K | 0.8% of assets |
| Accounts Receivable | $6M | 8.9% of assets |
| Inventory | $50K | 0.1% of assets |
| Total Liabilities | $22M | 33.7% of assets |
HCIL quarterly financials and insider trading
Hongchang International Co., Ltd (HCIL) industry peers
Companies classified under the same SEC industry code as Hongchang International Co., Ltd (Electromedical & Electrotherapeutic Apparatus): 32 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| HCIL Hongchang International Co., Ltd | ▶ | N/A |
| MDT Medtronic Plc | ▼ | $121.20B |
| ITGR Integer Holdings Corp | ▼ | $4.31B |
| LIVN Livanova Plc | ▼ | $4.27B |
| TMDX Transmedics Group, Inc. | ▲ | $2.45B |
| BLFS Biolife Solutions Inc | ▶ | $1.89B |
| AXGN Axogen, Inc. | ▲ | $1.86B |
| CNMD Conmed Corp | ▼ | $1.40B |
| CBLL Ceribell, Inc. | ▲ | $961M |
| INMD Inmode Ltd. | ▼ | $814M |
| CV Capsovision, Inc | ▶ | $327M |
| ELMD Electromed, Inc. | ▼ | $229M |
| FOCL Edap Tms Sa | ▲ | $153M |
| STXS Stereotaxis, Inc. | ▶ | $101M |
| VANI Vivani Medical, Inc. | ▶ | $101M |
| NRXS Neuraxis, Inc | ▲ | $97M |
| HYPR Hyperfine, Inc. | ▲ | $75M |
| OM Outset Medical, Inc. | ▲ | $74M |
| ECOR Electrocore, Inc. | ▲ | $71M |
| VASO Vaso Corp | ▲ | $51M |
| POSC Positron Corp | ▲ | $51M |
| QTI Qt Imaging Holdings, Inc. | ▶ | $35M |
| POCI Precision Optics Corporation, Inc. | ▲ | $34M |
| ITOC Itonic Holdings Ltd | ▶ | $28M |
| GTHP Guided Therapeutics Inc | ▲ | $18M |
| IRIX Iridex Corp | ▲ | $14M |
| NDRA Endra Life Sciences Inc. | ▶ | $7M |
| ADMT Adm Tronics Unlimited, Inc. | ▼ | $3M |
| NUWE Nuwellis, Inc. | ▶ | $2M |
| NXL Nexalin Technology, Inc. | ▼ | $2M |
| ESMC Escalon Medical Corp | ▶ | $1M |
| YBGJ Yubo International Biotech Ltd | ▶ | N/A |
Where HCIL sits on the market map
Hongchang International Co., Ltd (HCIL) stock news
Loading...
Hongchang International Co., Ltd (HCIL) stock forecast FAQ
What is the Hongchang International Co., Ltd (HCIL) stock forecast?
On Oct. 16, 2026, HCIL is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5184 stocks scored that day.
How accurate are Hongchang International Co., Ltd stock predictions?
For HCIL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 3.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 13.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Hongchang International Co., Ltd forecasts updated?
Hongchang International Co., Ltd forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Hongchang International Co., Ltd's industry peers?
32 issuers in our coverage, HCIL included, share the SEC industry code Electromedical & Electrotherapeutic Apparatus. The largest are: Medtronic Plc (MDT), Integer Holdings Corp (ITGR), Livanova Plc (LIVN), Transmedics Group, Inc. (TMDX), Biolife Solutions Inc (BLFS), Axogen, Inc. (AXGN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.